Close Menu

NEW YORK – Interpace Diagnostics said today that it has signed a contract with Blue Shield of California to cover its ThyGeNext and ThyraMir thyroid cancer detection assays as an in-network service, which will limit members' out-of-pocket expenses. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.